IL212086A0 - Ligands that have binding specificity for dc-sign - Google Patents

Ligands that have binding specificity for dc-sign

Info

Publication number
IL212086A0
IL212086A0 IL212086A IL21208611A IL212086A0 IL 212086 A0 IL212086 A0 IL 212086A0 IL 212086 A IL212086 A IL 212086A IL 21208611 A IL21208611 A IL 21208611A IL 212086 A0 IL212086 A0 IL 212086A0
Authority
IL
Israel
Prior art keywords
ligands
sign
binding specificity
specificity
binding
Prior art date
Application number
IL212086A
Other languages
English (en)
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of IL212086A0 publication Critical patent/IL212086A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
IL212086A 2008-10-21 2011-04-03 Ligands that have binding specificity for dc-sign IL212086A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10708508P 2008-10-21 2008-10-21
PCT/EP2009/063655 WO2010046337A2 (en) 2008-10-21 2009-10-19 Ligands that have binding specificity for dc-sign

Publications (1)

Publication Number Publication Date
IL212086A0 true IL212086A0 (en) 2011-06-30

Family

ID=42062429

Family Applications (1)

Application Number Title Priority Date Filing Date
IL212086A IL212086A0 (en) 2008-10-21 2011-04-03 Ligands that have binding specificity for dc-sign

Country Status (16)

Country Link
US (1) US20110257373A1 (enExample)
EP (1) EP2356149A2 (enExample)
JP (1) JP2012506237A (enExample)
KR (1) KR20110071139A (enExample)
CN (1) CN102257009A (enExample)
AR (1) AR073905A1 (enExample)
AU (1) AU2009306424A1 (enExample)
BR (1) BRPI0919714A2 (enExample)
CA (1) CA2740856A1 (enExample)
EA (1) EA201100488A1 (enExample)
IL (1) IL212086A0 (enExample)
MX (1) MX2011004244A (enExample)
TW (1) TW201019962A (enExample)
UY (1) UY32189A (enExample)
WO (1) WO2010046337A2 (enExample)
ZA (1) ZA201102763B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20110775A1 (es) * 2008-10-21 2011-10-21 Domantis Ltd Composicion para dirigirse a las celulas dendriticas
WO2013095973A1 (en) * 2011-12-19 2013-06-27 The Rockefeller University Hdc-sign binding peptides
US20250319024A1 (en) * 2021-08-27 2025-10-16 University Of Georgia Research Foundation, Inc. Targeted nanoparticles and their uses related to infectious disease
CN118184795B (zh) * 2022-12-13 2025-03-21 成都维瑾柏鳌生物医药科技有限公司 抗hiv-1的重组蛋白及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0598108A1 (en) * 1992-06-05 1994-05-25 Dade Produktions AG Rabbit single domain antibody and use thereof
JP2006519763A (ja) * 2002-11-08 2006-08-31 アブリンクス エン．ヴェー． 治療用ポリペプチドの投与法およびそのためのポリペプチド
EP2390270A1 (en) * 2003-01-10 2011-11-30 Ablynx N.V. Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
EP1627062A1 (en) * 2003-05-14 2006-02-22 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
DE602004017726D1 (de) * 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
JP4970035B2 (ja) * 2003-08-21 2012-07-04 リポテック・プロプライエタリー・リミテッド ｉｎｖｉｖｏにおける樹状細胞の標的化
AU2005250216B2 (en) * 2004-06-01 2009-12-10 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
CA2588892A1 (en) * 2004-12-02 2006-06-08 Dormantis Limited Anti-il-1r1 single domain antibodies and therapeutic uses
EP1841796A2 (en) * 2004-12-02 2007-10-10 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
KR20080003351A (ko) * 2005-03-18 2008-01-07 도만티스 리미티드 캔디다 항원에 대한 항체
KR20080090414A (ko) * 2005-12-06 2008-10-08 도만티스 리미티드 세포 표면 표적에 대한 결합 특이성이 있는 이중 특이성리간드 및 이의 사용방법
JP2009518024A (ja) * 2005-12-06 2009-05-07 ドマンティス リミテッド Ｅｇｆｒおよび／またはｖｅｇｆに対して結合特異性を有するリガンドおよびその使用法
AU2007209202A1 (en) * 2006-01-24 2007-08-02 Domantis Limited Ligands that bind IL-4 and/or IL-13
CA2663851A1 (en) * 2006-09-26 2008-04-03 Alexion Pharmaceuticals, Inc. Compositions and methods for enhancing an adjuvant
US20100143371A1 (en) * 2006-10-31 2010-06-10 Zhenping Zhu Intrabodies
CN101182539A (zh) * 2007-11-06 2008-05-21 浙江大学 Dc-sign启动子荧光素酶报告质粒的构建方法

Also Published As

Publication number Publication date
WO2010046337A3 (en) 2010-07-01
ZA201102763B (en) 2012-09-26
UY32189A (es) 2010-05-31
KR20110071139A (ko) 2011-06-28
AR073905A1 (es) 2010-12-09
MX2011004244A (es) 2011-05-25
WO2010046337A2 (en) 2010-04-29
EP2356149A2 (en) 2011-08-17
TW201019962A (en) 2010-06-01
BRPI0919714A2 (pt) 2015-12-08
US20110257373A1 (en) 2011-10-20
JP2012506237A (ja) 2012-03-15
CN102257009A (zh) 2011-11-23
CA2740856A1 (en) 2010-04-29
EA201100488A1 (ru) 2011-12-30
AU2009306424A1 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
AP2012006188A0 (en) Bispecific binding molecules for anti-angiogenesistherapy.
EP2250608A4 (en) CLOUD ASSOCIATION OF MOBILE COMPONENTS
IL212941A0 (en) Usirna complexes
GB201012195D0 (en) Catalysed filter
IL209664A0 (en) 5-substtuted isoindoline compounds
IL209727A0 (en) Pyridine compounds
EP2380639A4 (en) FIXING SNOWBOARD
GB0823686D0 (en) Holograms
ZA201105658B (en) Improved anti-serum albumin binding variants
EP2245153A4 (en) IMPROVED METHODS FOR PRODUCING SPECIFIC BINDING SAVINGS
IL214480A0 (en) Improved anti-serum albumin binding variants
IL212812A0 (en) Ligands that bind il-13
GB0906575D0 (en) Wire binding machines
EP2249646A4 (en) PDE4 muscarinic Antagonist-DOPPELPHARMACOPHOREN
GB0808886D0 (en) Dual purpose modulator
EP2259681A4 (en) DUAL PHARMACOPHORES, ANTAGONISTS OF MUSCARINIC RECEPTORS AND INHIBITORS OF PDE4 ACTIVITY
SG2014006878A (en) ßGI-IGG INTRON FOR ENHANCED ANTI-IGF1 R EXPRESSION
ZA201102763B (en) Ligands that have binding specificity for dc-sign
IL207351A0 (en) Dual pharmacophores - pde4 - muscarinic antagonistics
GB0713187D0 (en) biomolecule binding ligands
IL213675A0 (en) Chiral ligands
IL207346A0 (en) Dual pharmacophores - pde4 - muscarinic antagonistics
IL213445A0 (en) Anticancer compounds
EP2249830A4 (en) DUAL PHARMACOPHORES, ANTAGONISTS OF MUSCARINIC RECEPTORS AND INHIBITORS OF PDE4 ACTIVITY
GB0901231D0 (en) Ligands